: RSV vaccine for older adults provides protection over two seasons, GSK says

GSK’s GSK respiratory syncytial virus vaccine for older adults may protect against disease for two full RSV seasons, according to new results from a phase 3 trial the company released Wednesday. Similar efficacy was seen over two seasons in adults with underlying comorbidities and advancing age, the company said in a release. The U.S. Food and Drug Administration in May approved the vaccine, Arexvy, for prevention of RSV in people 60 and older. RSV is a highly contagious virus that causes lung and breathing-passage infections. GSK’s ADR is down 1.5% in the year to date, while the S&P 500 is up 14%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.